TY - JOUR
T1 - Mechanisms of resistance to CAR T cell therapies
AU - Singh, Nathan
AU - Orlando, Elena
AU - Xu, Jun
AU - Xu, Jie
AU - Binder, Zev
AU - Collins, McKensie A.
AU - O'Rourke, Donald M.
AU - Melenhorst, J. Joseph
N1 - Funding Information:
This work was supported by Novartis Institutes for Biomedical Research (ND, EO, JunX, ZB, DOR, JJM), RO1CA241762 (JJM), P01CA214278 (JJM) and the Parker Institute for Cancer Immunotherapy (MAC, JJM). Dr. Jie Xu is supported by a fellowship grant from the Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China .
Funding Information:
N.S., E.O., Z.B., D.M.O. and J .J.M. are listed as investors on patents related to CAR T cell therapy and owned by the University of Pennsylvania and Novartis. J.J.M. is a consultant for Shanghai Unicar, Simcere of America, IASO Biotherapeutics, and Poseida Therapeutics, and receives research funding from Incyte, Novartis and the Parker Institute for Cancer Immunotherapy. E.O. is an employee of Novartis.
Funding Information:
This work was supported by Novartis Institutes for Biomedical Research (ND, EO, JunX, ZB, DOR, JJM), RO1CA241762 (JJM), P01CA214278 (JJM) and the Parker Institute for Cancer Immunotherapy (MAC, JJM). Dr. Jie Xu is supported by a fellowship grant from the Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Publisher Copyright:
© 2019
PY - 2020/10
Y1 - 2020/10
N2 - Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.
AB - Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.
KW - Chimeric antigen receptor
KW - Resistance
UR - http://www.scopus.com/inward/record.url?scp=85076857159&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2019.12.002
DO - 10.1016/j.semcancer.2019.12.002
M3 - Review article
C2 - 31866478
AN - SCOPUS:85076857159
SN - 1044-579X
VL - 65
SP - 91
EP - 98
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -